Breaking News, Collaborations & Alliances

Neurimmune, Ono Expand Neurodegenerative Discovery Collaboration

Aims to generate and validate human-derived monoclonal antibodies against Ono's newly selected drug targets in the field of neurodegenerative diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

p.p1 {margin: 0.0px 0.0px 8.0px 0.0px; font: 11.0px ‘Trebuchet MS’} span.s1 {letter-spacing: 0.0px} Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. to create antibody drugs against new therapeutic targets in the field of neurodegenerative diseases using Neurimmune’s Reverse Translational Medicine (RTM) technology platform. In November 2017, Ono and Neurimmune signed a drug discovery collaboration to identify...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters